Dagmar F Hernandez-Suarez1, Stuart A Scott2, Matthew I Tomey3, Kyle Melin4, Angel Lopez-Candales5, Charlotte E Buckley6, Jorge Duconge7. 1. ORCID ID: 0000-0003-1850-9078, University of Puerto Rico School of Medicine, Medical Sciences Building, PO Box 365067, San Juan, 00936-5067, Puerto Rico. 2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Cardiovascular Medicine Division, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Department of Pharmacy Practice, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, USA. 5. Cardiovascular Medicine Division, University of Puerto Rico School of Medicine, San Juan, Puerto Rico, USA. 6. University of Michigan College of Pharmacy, Ann Arbor, MI, USA. 7. Pharmaceutical Sciences Department, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, USA.
Abstract
BACKGROUND: Clopidogrel is by far the most prescribed platelet adenosine diphosphate (ADP) antagonist in Puerto Rico despite the advent of newer agents (prasugrel and ticagrelor). Given the paucity of data on clopidogrel responsiveness in Hispanics, we sought to determine the association between clinical characteristics and platelet reactivity in Puerto Rican patients on clopidogrel therapy. STUDY POPULATION: A total of 100 Puerto Rican patients on clopidogrel therapy were enrolled and allocated into two groups: Group I, without high on-treatment platelet reactivity (HTPR); and Group II, with HTPR. Platelet function was measured ex vivo using the VerifyNow® P2Y12 assay. RESULTS: The cohort was comprised of Hispanic patients with coronary artery disease (57%), peripheral artery disease (32%), carotid artery stenosis (7%), cerebral artery aneurysm (2%), and stroke (2%). Mean platelet reactivity was 200 ± 61 P2Y12 reaction units (PRUs) (range: 8-324), and 35% of patients had HTPR (PRUs ⩾ 230). Multivariable logistic regression analysis determined that diabetes mellitus (DM) [odds ratio (OR) = 3.27; 95% confidence interval (CI): 1.20-8.96], use of proton-pump inhibitors (PPIs) (OR = 3.60; 95% CI: 1.09-11.82), and calcium channel blockers (CCBs) (OR = 3.10; 95% CI: 1.09-8.83) were independent predictors of HTPR ( p < 0.05) after adjusting for other clinical variables. CONCLUSIONS: In a sample of 100 Puerto Rican Hispanic patients on clopidogrel, 35% had HTPR. Furthermore, DM, PPIs and CCBs predicted HTPR. Clinical outcome data are needed to identify appropriate PRU thresholds for risk prediction in the Puerto Rican population.
BACKGROUND:Clopidogrel is by far the most prescribed platelet adenosine diphosphate (ADP) antagonist in Puerto Rico despite the advent of newer agents (prasugrel and ticagrelor). Given the paucity of data on clopidogrel responsiveness in Hispanics, we sought to determine the association between clinical characteristics and platelet reactivity in Puerto Rican patients on clopidogrel therapy. STUDY POPULATION: A total of 100 Puerto Rican patients on clopidogrel therapy were enrolled and allocated into two groups: Group I, without high on-treatment platelet reactivity (HTPR); and Group II, with HTPR. Platelet function was measured ex vivo using the VerifyNow® P2Y12 assay. RESULTS: The cohort was comprised of Hispanic patients with coronary artery disease (57%), peripheral artery disease (32%), carotid artery stenosis (7%), cerebral artery aneurysm (2%), and stroke (2%). Mean platelet reactivity was 200 ± 61 P2Y12 reaction units (PRUs) (range: 8-324), and 35% of patients had HTPR (PRUs ⩾ 230). Multivariable logistic regression analysis determined that diabetes mellitus (DM) [odds ratio (OR) = 3.27; 95% confidence interval (CI): 1.20-8.96], use of proton-pump inhibitors (PPIs) (OR = 3.60; 95% CI: 1.09-11.82), and calcium channel blockers (CCBs) (OR = 3.10; 95% CI: 1.09-8.83) were independent predictors of HTPR ( p < 0.05) after adjusting for other clinical variables. CONCLUSIONS: In a sample of 100 Puerto Rican Hispanic patients on clopidogrel, 35% had HTPR. Furthermore, DM, PPIs and CCBs predicted HTPR. Clinical outcome data are needed to identify appropriate PRU thresholds for risk prediction in the Puerto Rican population.
Entities:
Keywords:
Hispanics; Puerto Rico; clopidogrel; platelet reactivity
Authors: Giuseppe Patti; Annunziata Nusca; Fabio Mangiacapra; Laura Gatto; Andrea D'Ambrosio; Germano Di Sciascio Journal: J Am Coll Cardiol Date: 2008-09-30 Impact factor: 24.094
Authors: P D Larsen; L R Johnston; A Holley; A C La Flamme; L Smyth; E W Chua; M A Kennedy; S A Harding Journal: Intern Med J Date: 2015-05 Impact factor: 2.048
Authors: P L Lutsey; M Cushman; L M Steffen; D Green; R G Barr; D Herrington; P Ouyang; A R Folsom Journal: J Thromb Haemost Date: 2006-09-26 Impact factor: 5.824
Authors: Carol A Derby; Rachel P Wildman; Aileen P McGinn; Robin R Green; Alex J Polotsky; Kavitha T Ram; Janice Barnhart; Gerson Weiss; Nanette Santoro Journal: Ethn Dis Date: 2010 Impact factor: 1.847
Authors: Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine Journal: N Engl J Med Date: 2008-12-22 Impact factor: 91.245
Authors: Lakshmana K Pendyala; Rebecca Torguson; Joshua P Loh; Joseph M Devaney; Fang Chen; Hironori Kitabata; Sa'ar Minha; Israel M Barbash; William O Suddath; Lowell F Satler; Augusto D Pichard; Ron Waksman Journal: Am Heart J Date: 2013-05-23 Impact factor: 4.749
Authors: Thomas Gremmel; Sabine Steiner; Daniela Seidinger; Renate Koppensteiner; Simon Panzer; Christoph W Kopp Journal: Heart Date: 2009-08-16 Impact factor: 5.994
Authors: S A Scott; J-P Collet; U Baber; Y Yang; I Peter; M Linderman; J Sload; W Qiao; A S Kini; S K Sharma; R J Desnick; V Fuster; R J Hajjar; G Montalescot; J-S Hulot Journal: Clin Pharmacol Ther Date: 2016-06-20 Impact factor: 6.875
Authors: Dagmar F Hernandez-Suarez; Hector Núñez-Medina; Stuart A Scott; Angel Lopez-Candales; Jose M Wiley; Mario J Garcia; Kyle Melin; Karid Nieves-Borrero; Christina Rodriguez-Ruiz; Lorraine Marshall; Jorge Duconge Journal: Drug Metab Pers Ther Date: 2018-03-28
Authors: Dagmar F Hernandez-Suarez; Jonnalie C Tomassini-Fernandini; Angelica Cuevas; Anyelis N Rosario-Berrios; Héctor J Nuñez-Medina; Dariana Padilla-Arroyo; Nannette Rivera; Jennifer Liriano; Rocio K Vega-Roman; Jessicca Y Renta; Kyle Melin; Jorge Duconge Journal: Int J Environ Res Public Health Date: 2018-05-30 Impact factor: 3.390